Background Antiretroviral therapy (ART) and retention in care are essential for the prevention of mother-to-child HIV transmission (PMTCT). We aimed to assess the eff ect of a family-focused, integrated PMTCT care package.
Introduction
Activities that result in successful prevention of mother-to-child HIV transmission (PMTCT) have transformed the delivery of HIV services for infants and mothers. The most crucial intervention along the PMTCT continuum of care is antiretroviral therapy (ART). If given promptly, consistently, and correctly, ART is highly eff ective in decreasing vertical HIV transmission. 1 However, gaps along the care continuum continue to constrain the ability of PMTCT programmes to stem the tide of perinatal HIV infections, especially in resourcelimited, rural settings. 2 Specifi cally, early ART initiation and retention in care, two crucial elements for the prevention of mother-to-infant HIV transmission and improvement of survival of the mother and infant pair, 3 are increasingly problematic for many PMTCT programmes in sub-Saharan Africa. 4 Nigeria is a major contributor to the global gap in elimination of mother-to-child HIV transmission, accounting for the largest proportion of new HIV infections in children worldwide. 5, 6 Among the many barriers to eff ective delivery of PMTCT services in Nigeria are the shortage of trained, skilled health-care providers, especially in rural areas; 7 delays in care associated with a dearth of reliable and aff ordable laboratory infrastructure; 8 customs that limit a woman's autonomy to make independent health-care decisions, including the absence of men participating in PMTCT services; 9, 10 and poorly integrated maternal and child health and HIV services. 11 To address these impediments to eff ective PMTCT care and the elimination of mother-to-child HIV transmission, we used a systematic, multipronged approach. We present fi ndings from an innovative trial in rural Nigeria that includes task shifting, point-of-care testing, integration of services for HIV-infected women and their exposed infants, and involvement of male partners and peer mentors as a package of services for PMTCT programmes in resource-limited settings.
Methods

Study design and participants
The design of this parallel, cluster-randomised controlled trial has been described previously. 12 Briefl y, the study took place at 12 sites located in the rural Niger state of north-central Nigeria, one of two states with clinical sites supported by Friends in Global Health, Vanderbilt University's implementation partner for the US President's Plan for AIDS Relief (PEPFAR). The intervention facilities included a comprehensive health centre in Agwara, rural hospitals in Kaffi n Koro, Agaie, and Auna, a National Council of Women's Societies clinic in Farin Doki, and a basic health clinic in Wuse. Matched standard-of-care (control) sites included maternal and child health clinics in Paiko and Chanchaga; basic health clinics in Ijah, Garam, and Izom; and a primary health clinic in Gauraka.
We included HIV-infected women (age was not included in the elegibility criteria, but the youngest participant was 16 years old) and their infants, presenting for antenatal care or delivery who met one of the following inclusion criteria: unknown HIV status at time of presentation; history of antiretroviral prophylaxis or treatment, but not receiving prophylaxis or treatment at the time of presentation; or known HIV status but had never received treatment. HIV-infected women who were on antiretroviral prophylaxis or treatment at the time of presentation to antenatal care were excluded from the study.
Ethical approval was obtained from the Nigeria National Human Research Ethics Committee and the Institutional Review Board of Vanderbilt University, USA. Consent was given orally.
Randomisation and masking
Sites were matched with each other and then randomly assigned by computer-generated sequence within matched pairs to deliver integrated PMTCT (n=6) or the standard of care (n=6). Matching was based on monthly antenatal clinic volume, number of HIV-infected patients seen
Research in context
Evidence before this study We searched PubMed, Web of Science, Ovid MEDLINE, the Cochrane Register of Clinical Trials, and the Cochrane Database of Systematic Reviews for articles on task shifting, male involvement in prevention of mother-to-child HIV transmission (PMTCT), integration of mother and infant care, and point-of-care CD4 cell count testing that were published between Jan 1, 1995, and Dec 31, 2015. We included published randomised controlled trials, cluster-randomised trials, controlled before-and-after studies, population-based retrospective cohort studies, and systematic reviews that emerged with the broad MeSH terms "HIV infections/ prevention & control", "Africa south of the Sahara", "health services accessibility", and "point-of-care systems". We narrowed the search by selecting for the following terms in identifi ed articles: "task shifting", "male participation", "antiretroviral treatment initiation", "retention in care", "CD4 point-of-care testing", and "PMTCT integration". The search was done by a research assistant. Investigators selected eligible studies for review, taking into consideration the methodological quality of identifi ed papers. Known barriers to eff ective PMTCT scale-up in Nigeria and similar settings in sub-Saharan Africa include shortages of skilled health-care providers who are trained in HIV prevention, especially in rural settings; absences of reliable and aff ordable laboratory infrastructure, particularly point-of-care diagnostics; cultural norms that inhibit participation of men in antenatal care; and fragmented maternal and child health services. Evidence-based solutions to these challenges are known; examples include task shifting, community-based and facility-based male engagement initiatives, couple counselling and testing, point-of-care CD4 cell count testing, and post-partum integration of services for HIV-infected mothers and their babies. A systematic approach that tackles these problems in a holistic manner has, however, not been rigorously assessed.
Added value of this study
This parallel, cluster-randomised trial shows that a package of individual PMTCT interventions that have independently been eff ective in increasing uptake of HIV services and improving antiretroviral treatment outcomes (task shifting, point-of-care CD4 cell count testing, integrated mother and infant service provision, and male partner and community engagement) increases maternal antiretroviral treatment uptake and mother and infant retention in care, decreases infant HIV infection, and is feasible in rural venues.
Implications of all the available evidence
Packaging of individually eff ective PMTCT interventions can have positive and measurable eff ects on important PMTCT outcomes. In view of Nigeria's sizeable contribution to the global burden of mother-to-child HIV transmission, an eff ective approach to improve the quality of PMTCT service delivery will positively aff ect global goals for the elimination of this transmission.
during the past 6 months, urbanisation of the area, and site accessibility. For the matching procedure, a distance matrix was generated by the study biostatistician (MB) that described the pairwise similarity between all sites based on the characteristics mentioned and weighting these charact eristics based on their perceived matching importance (the weight we assigned to each variable used in the matching, generated by a distance matrix). Optimum non-bipartite matching was used to minimise the average reweighted Mahalanobis distance between pairs. 13 The web application used to do non-bipartite matching is available online. Enrolment was done by clinic staff , with active oversight by study research staff , and were involved in the rest of the trial. There was no masking of participants, staff , or investigators.
Procedures
The procedures used across intervention and control groups have been described previously. 12 Briefl y, for the control group, we referred HIV-positive women to nearby secondary level, comprehensive clinics supported by Friends in Global Health for clinical and laboratory assessment and ART initiation. Pregnant women with advanced WHO clinical stage disease (WHO stage 3 or 4) or advanced immunosuppression (CD4 count <350 cells per μL) were initiated on ART for their own health, or placed on ART as prophylaxis if they did not qualify for ART for their own health (option B). Breastfeeding mothers were continued on ART until 1 week after breastfeeding ceased and stayed under the care of the referral centre. HIV-exposed infants were started immediately after birth on once daily nevirapine 10 mg in babies weighing less than 2·5 kg or once daily nevirapine 15 mg in babies weighing 2·5 kg or more for 6 weeks, as per Nigerian guidelines. 14 Mothers were asked to bring their infants back to the clinic at 6 weeks for follow-up, continuation of nevirapine (if mother was not compliant with ART and was breastfeeding), immunisations, initiation of co-trimoxazole prophylaxis, and early infant diagnosis testing.
The intervention sites received an integrated package of PMTCT services in maternal and child health settings that included point-of-care CD4 cell count or percentage testing, transition of decentralised PMTCT tasks to trained midwives (task shifting), integrated mother and infant care services, active infl uential family member (male partner) participation, and community involvement.
For same-day point-of-care CD4 cell count or percentage testing the CyFlow miniPOC system (PartecGmbH, Görlitz, Germany) was installed in each intervention site. This system is a user-friendly instrument well suited for resource-limited settings. Clinic staff were trained in sample collection and internal quality control.
A three-pronged strategy (training, on-site mentoring, and continuous quality assurance) was used for the task-shifting intervention. A minimum of three staff members (two nurses or midwives, one community health worker, and one pharmacist or pharmacy technician was included when available) from each intervention site had 5 day training with adopted curriculums. 15 A medical offi cer provided regular on-site mentoring and consultation for complex cases. Our taskshifting intervention was not substantially staff -intensive because no new staff were hired (all participating staff were already working in the sites, but the scope of their responsibilities was expanded), and training was done for all participating staff at the same time.
We integrated mother and infant services in the postpartum period by comanaging mother and infant pairs in the maternal and child health clinic and scheduling mother and infant visits to occur on the same visit date to reduce visit burden. Infants who tested positive for HIV were initiated on ART at the maternal and child health clinic and monitored throughout the study.
Men were encouraged to take part in their wives' antenatal care via personalised invitation letters handed out to all women who tested positive for HIV and presented for antenatal care without their partner. During the antenatal visit, clinicians educated male partners on the importance of PMTCT, tested the partners, and encouraged them to support their family. Man-friendly health settings were created in intervention facilities by training health-care staff and amending standard operational procedures to include men in all prenatal and postnatal appointments. Health facilities were altered to allow privacy for couple counselling and testing. A male counsellor was made available to see men who preferred to receive counselling from a man. The community component included recruitment and training (by six peer mentors per intervention clinic) of spouses of HIV-positive women enrolled in the study as community mobilisation champions so that they could educate others and share their own experience. The champion role included organising outreach activities to raise awareness of involvement of men in PMTCT; educating and encouraging men to accompany their spouses to PMTCT clinics; educating men about safe sex practices; distributing condoms; linking men to key referral services such as couples counselling and testing, services for sexually transmitted infections, and family planning; and soliciting the support of community leaders and infl uential family members through one-on-one interactions and community forums. Peer male champions were paid a small monthly stipend (NGN2000, equivalent to US$10) to support their transpor costs.
Participants in both intervention and control sites received group health education, opt-out HIV testing, same-day HIV test results, counselling on infant feeding, home-based care services, infant prophylaxis, early infant diagnosis, and linkage to family spacing services, if desired. No new interventions were started during the study.
We tracked demographic, PMTCT, and HIV care and treatment data that were routinely collected by our PMTCT programme and documented in the WHO HIV care/ART card or management of patients and monitoring forms for all women included in the study. Specifi c clinical and laboratory data from these forms were entered by research assistants into CAREWare (JPROG, New Orleans, LA, USA), an electronic medical record system adapted at supported sites and REDCap, a secure, web-based electronic data capture instrument hosted at Vanderbilt University. 16 
Outcomes
The primary outcomes were to compare between the intervention and control groups both the proportion of eligible women who initiated antiretroviral medications for PMTCT and the proportion of HIV-infected women and their infants retained in care at 6 weeks and 12 weeks post partum. We also compared HIV incidence in infants at 6 weeks and 12 weeks across control and intervention groups; however, this was a secondary outcome because the study was not powered to measure this aim.
ART initiation was defi ned as having occurred if there was a record that ART was prescribed in patients' folders and the fi rst medication pick-up was completed during pregnancy or up to 1 day post partum. Mother and infant retention at 6 weeks was defi ned as mother initiating ART, mother having a follow-up visit 4-8 weeks after delivery, and child having blood drawn for HIV DNA PCR testing 4-14 weeks after birth. Mother and infant retention at 12 weeks was similarly defi ned, the only diff erence being that the follow-up visit window was 10-14 weeks after delivery.
Only DNA PCR results at or after 4 weeks post partum were used to establish HIV incidence. The time of infection was set as the midpoint between the last HIV-negative and the fi rst HIV-positive result, or the midpoint between birth and the fi rst HIV-positive result, if the infant did not have a previous HIV-negative test. Date of death was recorded according to clinic records and maternal or family member report. Event time for stillborn infants was set immediately post partum (1 day).
Statistical analysis
With 12 clinics recruiting roughly 25 eligible patients each (n=300), we projected 90% power to detect a diff erence between 40% for six control clinics and 65% for six matched intervention clinics (coeffi cient of variation equal to 0·12 and probability of type I error equal to 0·05). 12 An intention-to-treat approach was used for all analyses. To compare the proportion of eligible women who initiated antiretroviral treatments for PMTCT between the intervention and control groups, we used a generalised linear mixed eff ects model with a log link function, study site and matched pairs were included as nested random eff ects, and a fi xed eff ect was used for randomisation to the intervention group. Covariates included in the mixed eff ects model that were specifi ed a priori as being important to ART initiation and retention were mother's age, years of education, travel time to the facility, employment status, ethnicity, and time of HIV diagnosis (before or during antenatal care vs delivery). Similar models were used to establish the eff ect of the intervention on retention of mother and infant pairs on ART at 6 weeks and 12 weeks. For the primary retention analyses, mother and infant pairs were excluded if either died, transferred to another site, or relocated within 14 weeks of birth. The adjusted models were also estimated with post-hoc adjustment variables to assess the robustness of our conclusions to patient-level diff erences in CD4 cell count and gestational age across groups. These post-hoc models needed multiple imputation to account for substantial missing CD4 cell count records.
The cumulative incidence of HIV infection for infants during their fi rst 12 weeks was computed treating death as a competing risk. Infants were censored at their last clinic visit or at 12 weeks post partum. We used non-parametric methods to estimate the cumulative incidence function. Confi dence intervals were calculated with the delta method, and Gray's method was used to test for diff erences across study group. 17 The probability of death and the probability of the composite endpoint of HIV infection or death for infants were computed with Kaplan-Meier techniques, censoring infants at the date of last clinic visit or at 12 weeks post partum. Separate Cox regression models were used to assess the eff ect of randomisation to intervention on infant HIV infection, death, and the composite endpoint of HIV infection or death. Models were adjusted for the same covariates listed previously (a priori and post hoc) and stratifi ed by site; robust covariance estimation was used to account for clustering of twins (n=22) within mothers. Sensitivity analyses were done to investigate the eff ect of poor retention on the combined endpoint of HIV infection or death; infants of mothers who did not receive ART treatment were assigned a probability of infection equal to 0·035 for power calculations (or 0·07, which was closer to the observed cumulative incidence of HIV infection in control-group participants) and infants of mothers who were not retained in care at 6 weeks were assigned a probability of infection equal to 0·017 (or 0·035). HIV status for eligible infants was randomly imputed with the Bernoulli distribution, the interval time was assigned as 84 days, and Cox regression models were done. This step was repeated ten times and estimates from the multiple regressions were combined with multiple imputation techniques. R-software (version 3.0.2) was used for data analyses). The trial is registered with ClinicalTrials.gov, number NCT01805752.
Roles of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit the manuscript for publication. The corresponding author had full access to all the data and had fi nal responsibility for the decision to submit for publication.
Results
Within the 12 rural sites randomly assigned to deliver either the intervention package or the standard of care, 372 HIV-infected women gave consent and were enrolled into the study between April 1, 2013, and March 31, 2014 between 25 and 30 women were screened at each of the 12 sites, 172 (46%) of whom were eligible in the intervention group and 197 (53%) in the control group (fi gure 1). Most participants were married, homemakers, and enrolled in Sabon Wuse hospital (intervention) or Garam Hospital (control; table 1). Almost all enrolled women were newly diagnosed as HIV-infected while attending antenatal care. At enrolment, gestational age was later for participants in the intervention group than for those in the control group. Participants in the intervention group were slightly younger than those in the control group. More than a quarter of all participants had no formal education; this proportion was higher in the intervention than in the control group. Participants were similar across groups for time of HIV diagnosis, distance to facility, and marital status. Participants did not diff er across groups by bodyweight, functional status, WHO clinical stage, and mode of delivery. Most participants had WHO clinical stage 1 disease and a high functional status (working or ambulatory). Median CD4 cell count at enrolment was higher for mothers in the intervention group than for those in the control group. Most births occurred at term (37-42 weeks; table 2) at home and by vaginal delivery. Four mothers died during the study; however, maternal deaths were not associated with HIV-related illness (table 1).
The proportion of male partners who accompanied (at least once) their partners over the course of the study was greater in the intervention than in the control group. Similarly, the proportion of male partners who were tested for HIV at intervention site antenatal clinics was greater than those who tested at control sites. Of the male partners tested during antenatal care, a smaller proportion of those were HIV-positive when tested at the intervention sites than were those tested at the control sites. However, HIV status was not available as a result of no HIV testing during antenatal care or self-report for 45% of male partners (table 1) . 166 (97%) women initiated ART in the intervention group compared with only 77 (39%) in the control group. Among the women who initiated ART, the median duration of treatment before delivery was 10 weeks (IQR [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] for those in the intervention group and 21 weeks (10-32) for those in the control group. After adjustment for maternal age, education, travel time to facility, employment, maternal ethnicity, and time of HIV diagnosis, mothers in the intervention group were more likely to initiate ART than mothers in the control group (adjusted relative risk [RR] 3·3, 95% CI 1·4-7·8; table 3) .
380 neonates were born to the 369 study participants, and no signifi cant diff erences were noted in birthweight and birth length between study groups (table 2) . Almost all infants for whom breastfeeding data were available were ever breastfed (table 2) . Fewer babies born to mothers in the intervention group did not receive any nevirapine in the post-partum period compared with babies born to women in the control group (table 2) . Only nine (5%) infants born to mothers in the intervention group were lost to follow-up before study termination compared with 101 (50%) of infants born to mothers in the control group. 70 infants (including fetal death) died across both groups during the study (table 2) , and the cause of fetal or infant death was unknown in 28 (41%) cases.
The proportion of mother and infant pairs retained in the intervention group at 6 weeks post partum was 0·83 (125 of 150 pairs) and at 12 weeks post partum was 0·75 (112 of 150 pairs). By contrast, the proportion of mother and infant pairs retained in the control group at 6 weeks post partum was 0·09 (15 of 170 pairs) and at 12 weeks was 0·07 (11 of 168 pairs). After adjustment for maternal age, education, travel time, employment, ethnicity, and time of HIV diagnosis, mother and infant pairs in the intervention group were roughly ten times more likely to be retained in care at 6 weeks (adjusted RR 9·1, 95% CI 5·2-15·9) and 12 weeks (10·3, 5·4-19·7) post partum than were pairs in the control group (table 3) .
Three infants in the intervention group and fi ve infants in the control group were infected with HIV at Mother and infant retention at 12 weeks
Control group as reference. Study site and matched pair are included as nested random eff ects. Adjustment variables include maternal age, years of education, travel time to facility, employment status, ethnicity of mother, and time of HIV diagnosis (before antenatal care or during antenatal care vs delivery). Post-hoc adjustment includes the aforementioned plus gestational age and CD4 cell count with multiple imputation (because CD4 cell count had substantial missing data). The scale parameter for all Poisson mixed models was between 0·50 and 0·65, suggesting an absence of model overdispersal. If a mother gave birth to two children then testing status was confi rmed to be the same for both infants and the mother and infant status was only counted once. RR=relative risk. . Similarly, in sensitivity analyses in which infants who were lost to follow-up were assumed to have been infected at rates specifi ed in the Methods section, the eff ect of intervention on HIV infection became inconclusive (appendix). At 12 weeks post partum, infants born to mothers in the intervention group were also 18% less likely to have died than were those born to mothers in the control group, but this diff erence was not signifi cant (aHR 0·82, 0·47-1·43; p=0·49; fi gure 2). Similar results were noted for the composite outcome of infant HIV infection or death at 12 weeks post partum (0·72, 0·42-1·22; p=0·22).
Discussion
This parallel, cluster-randomised trial from rural Nigeria showed a large eff ect of a creative package of PMTCT services on three important outcomes: maternal ART initiation, early maternal and infant retention in care, and HIV infection in infants at 12 weeks. Mothers in the intervention group were three times as likely to initiate ART as women in the control group, and mother and infant pairs had a roughly ten times higher rate of retention at 6 weeks and 12 weeks post partum than did pairs in the control group. More importantly, our intervention signifi cantly reduced incident HIV infection in infants, with those in the intervention group being 74% less likely to be diagnosed with HIV at 12 weeks than those in the control group. Reduced HIV infection was not a primary outcome in our study because we did not expect such a large diff erence between the two groups and expected to be underpowered for this defi nitive endpoint. The potential for our intervention to have a major eff ect on public health is better appreciated within the context of Nigeria's sizeable burden of vertical HIV transmission and continued reports of suboptimum PMTCT outcomes. In 2010, only 8% of eligible HIV-infected women were off ered antiretroviral drugs to prevent vertical HIV transmission. 18, 19 With a national HIV prevalence rate of 4·1% in antenatal attendees (>200 000 HIV-infected pregnant women), 20, 21 Nigeria alone contributed 29% of the global gap in reaching 90% of pregnant women in need of PMTCT services. 19, 21 Services for HIV-exposed or HIV-infected children have been even more dismal. In 2010, only 6% of HIV-exposed infants in Nigeria received any form of HIV prophylaxis or treatment, falling far short of the 90% national target. 19 Interventions that eff ectively stem the tide of vertical HIV transmission in Nigeria will probably have a substantial eff ect on global goals for the elimination of mother-to-child HIV transmission.
Individual components of the package of services provided in this study (point-of-care CD4 testing, task shifting, male involvement, and integration of mother and child services) have previously been eff ective in increasing uptake of HIV services and improving antiretroviral treatment outcomes across diff erent locations. [22] [23] [24] [25] [26] Our study shows that putting these components into use as a package of services in rural settings is feasible. Our fi ndings also suggest that lower-cadre health workers can be eff ectively used to bridge the gap in human resource capacity and provide HIV care and treatment in PMTCT programmes in analogous environments, an important fi nding given that most service providers in Nigeria are concentrated in urban health centres. 7 Although our report does not allow us to tease out which components of the intervention had the largest eff ect, our fi ndings suggest that in combination they can greatly improve the PMTCT cascade.
Early initiation of ART has proven benefi ts, including improved maternal and infant survival, accelerated immune recovery, and reduced transmission of HIV. 27, 28 The advent and gradual scale-up of option B+ (lifelong combination ART for all HIV-infected pregnant and breastfeeding women, irrespective of clinical stage or CD4 cell count) across Africa, although not yet adopted by Nigeria, is an opportunity to explore new strategies for improving uptake of ART and long-term retention of mother and infant pairs. Although option B+ will increase the pool of patients eligible for treatment, it will also make CD4 cell count testing redundant for decision making about initiation of ART by pregnant women. However, CD4 cell count testing will probably continue to be useful as a valuable method for monitoring response to treatment, especially in resource-limited settings. Our fi ndings suggest that other user-friendly point-of-care diagnostics (eg, viral load testing) that improve the effi ciency of referrals can help to improve treatment initiation and retention in PMTCT programmes.
Cultural norms in Nigeria, (particularly gender disparities) have a major role in women's self-autonomy and ability to make independent decisions about their health care, especially when it relates to reproductive health. 9, 10 Our study location (northern Nigeria) has historically low rates of male involvement in maternity care. 9 Our study suggests that a male partner intervention that is part of a package of PMTCT services and includes a combination of individual, facility-based, and com munity-based approaches (invitation letters delivered by wives, peer male champions, and See Online for appendix male-friendly settings) is acceptable and feasible. The use of invitation letters and tracing to recruit male partners for couple HIV testing and counselling has been eff ective in option B+ settings, 29 and could prove feasible in our environment when option B+ becomes national policy. Our study also shows that male partners can provide assistance in the use of culturally sensitive and sustainable PMTCT care delivered by lower-cadre providers. The eff ect of active male engagement on ART uptake in our study is consistent with other reports. 25 Our study has limitations: our protocol did not include measurement of outcomes in male partners, an oversight that would have otherwise added value to our under standing of the role of men in PMTCT. Our analyses also deemed women who transferred clinics without notifi cation as failed retention, a reasonable assumption, since relocations and clinic transfers (silent transfers) are a common cause of non-mortality losses in HIV programmes. 30 We were also unable to show whether our intervention aff ected viral load suppression, because viral load testing was not done in our setting. We also had to assess retention at an earlier timepoint than the national cutoff point for loss to follow-up (mother and baby >90 days late for an appointment at 6 months post partum) because of time constraints associated with the grant period. Because many infants might still have been breastfeeding at the time of the 6 week and 12 week DNA PCR testing, our results might overestimate the true HIV-free survival rate in this cohort. We only knew the HIV status of infants who were retained, and this diff ered by intervention group. Infants who were not retained might have been more likely to be HIV-infected, and therefore the relative risk eff ect of the intervention on infant HIV infection might actually be greater than that reported here. Although study sites were randomly assigned, participants in the control and intervention groups had diff erences that could have aff ected our study outcomes. The fi nding that women in the intervention group were less well educated and came to antenatal care later in gestation might be biased towards the null hypothesis, whereas the higher CD4 cell counts in women in the intervention group might be a bias away from the null hypothesis. The observed cluster size was not uniform, and our regression analysis makes the most effi cient use of the data by giving more weight to clusters that provide more information because of a larger sample size; thus, smaller sites have less infl uence on the results. Because the intervention group had more staffi ng and ongoing quality assurance activities, the completeness or correctness of data might be better at the intervention sites. Diff erences in risk of infant death between study groups could aff ect diff erences in rates of uptake of early infant diagnosis in an intention-to-treat analysis. However, risk of infant death was not signifi cantly diff erent between study groups. The strengths of our study include the cluster-randomised design, a large cohort drawn across 12 busy PMTCT sites, a mixed-methods approach to monitoring the inter vention, and a prospective design that favours causal inference.
In summary, we have shown that a culturally sensitive bundle of PMTCT services improves treatment uptake and mother and infant retention in care, decreases infant HIV infection, is feasible in rural venues, and has the potential to enable Nigeria's attainment of elimination of mother-to-child HIV transmission goals. National policies that address inclusion of lower-cadre service providers, engage men in the community, integrate maternal and child health and HIV services, and support provision of point-of-care diagnostics in resource-constrained settings will help to stem vertical HIV transmission, save lives, and optimise maternal and infant outcomes. As previously advocated by others, 31 a robust implementation research framework will generate the evidence basis for adopting best practices needed to overcome the challenges impeding eff ective implementation of PMTCT programmes in real-world settings.
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